NCT04703374 - A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions

GERD

Interventions

DRUG

CKD-382(formulation I)

1 tablet administered under fasting condition for 7days

DRUG

CKD-382(formulation II)

1 tablet administered under fasting condition for 7days

DRUG

D026

1 tablet administered under fasting condition for 7days

Trial Locations (1)

RECRUITING

Chungbuk National University Hospital, Cheongju-si